Prior to the advent of selective RET inhibition, patients with RET-rearranged NSCLC treated with conventional therapies in the United States, including chemotherapy and immunotherapy, demonstrated similar survival outcomes when compared to patients with RET wild-type NSCLC in a retrospective analysis [60]. The gene discussed is RET; the disease is non-small cell lung carcinoma.